Influence of patient characteristics and immunosuppressant management on mortality in kidney transplant recipients hospitalized with coronavirus disease 2019 (COVID-19).
Adrenal Cortex Hormones
/ therapeutic use
Adult
Aged
COVID-19
/ mortality
Female
Graft Rejection
/ epidemiology
HIV Infections
Humans
Immunosuppression Therapy
Immunosuppressive Agents
/ therapeutic use
Kidney Transplantation
/ mortality
Male
Middle Aged
Mycophenolic Acid
/ therapeutic use
Retrospective Studies
Risk Factors
Tacrolimus
/ therapeutic use
Transplant Recipients
COVID-19
immunosuppressive agents
kidney transplantation
transplant recipients
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
17
12
2020
received:
11
09
2020
accepted:
22
12
2020
pubmed:
10
1
2021
medline:
28
5
2021
entrez:
9
1
2021
Statut:
ppublish
Résumé
The influence of patient characteristics and immunosuppression management on COVID-19 outcomes in kidney transplant recipients (KTRs) remains uncertain. We performed a single-center, retrospective review of all adult KTRs admitted to the hospital with confirmed COVID-19 between 03/15/2020 and 05/15/2020. Patients were followed from the date of admission up to 1 month following hospital discharge or study conclusion (06/15/2020). Baseline characteristics, laboratory parameters, and immunosuppression were compared between survivors and patients who died to identify predictors of mortality. 38 KTRs with a mean baseline eGFR of 52.5 ml/min/1.73 m
Identifiants
pubmed: 33421213
doi: 10.1111/ctr.14221
pmc: PMC7995120
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunosuppressive Agents
0
Mycophenolic Acid
HU9DX48N0T
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14221Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK122164
Pays : United States
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Am J Transplant. 2020 Jul;20(7):1780-1784
pubmed: 32243677
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Am J Transplant. 2020 Jul;20(7):1809-1818
pubmed: 32282982
Am J Transplant. 2020 Nov;20(11):3008-3018
pubmed: 32780493
Clin Infect Dis. 2021 Dec 6;73(11):e4090-e4099
pubmed: 32766815
Int J Pediatr Endocrinol. 2016;2016:17
pubmed: 27688786
Clin Transplant. 2021 Apr;35(4):e14221
pubmed: 33421213
Nat Commun. 2018 Jun 8;9(1):2229
pubmed: 29884817
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Am J Transplant. 2020 Nov;20(11):3051-3060
pubmed: 32654332
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
N Engl J Med. 2020 Jun 18;382(25):2475-2477
pubmed: 32329975
J Am Soc Nephrol. 2021 Jan;32(1):151-160
pubmed: 32883700
Lancet. 2020 May 23;395(10237):e95-e96
pubmed: 32407668
J Am Soc Nephrol. 2020 Jul;31(7):1380-1383
pubmed: 32366514
Kidney Int Rep. 2020 Jun 25;5(8):1149-1160
pubmed: 32775814
N Engl J Med. 2020 Oct 29;383(18):1757-1766
pubmed: 32329974
Singapore Med J. 2014 Jul;55(7):372-7
pubmed: 25091886
Am J Transplant. 2020 Jul;20(7):1765-1767
pubmed: 32233057